What drove the significant increase in net sales?

Net sales increased by 20% to $846.9 million, driven by an 11% increase in unit volume and product mix, 5% from favorable foreign currency exchange rates, 2% from higher selling prices, and 2% from acquired businesses and product lines. Both domestic and international sales showed strong growth.

How did the company's profitability change?

Profitability improved considerably, with net earnings rising 28% to $104.1 million. This was supported by a higher gross profit margin (64.5% vs. 63.7%) due to favorable product mix and lower cost of sales as a percentage of sales. The effective income tax rate also decreased to 31.0% from 33.0%.

What is the company's liquidity and cash flow position?

Stryker generated strong operating cash flow of $104.2 million, a significant increase from the prior year, which was used to fund capital expenditures ($29.2 million), acquisitions ($4.3 million), and dividends ($23.8 million). The company also managed its debt levels, with total borrowings declining by $52.8 million in the quarter. The company has substantial borrowing capacity available under its credit facilities and believes its cash on hand and anticipated cash flows are sufficient to meet future needs.

What are the key segments contributing to the company's performance?

The company's two main reportable segments, Orthopaedic Implants and MedSurg Equipment, both performed well. Orthopaedic Implants saw a 24% sales increase, driven by reconstructive, trauma, and spinal implants. MedSurg Equipment sales grew 18%, fueled by powered surgical instruments, endoscopic systems, and hospital beds. Physical Therapy Services also contributed positively with a 5% revenue increase.

SYK 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Stryker Corporation reported a strong first quarter for 2003, with net sales increasing by 20% year-over-year to $846.9 million. This growth was driven by robust performance in both its Orthopaedic Implants and MedSurg Equipment segments, with international sales showing particularly strong momentum, up 27%. The company also demonstrated improved profitability, with net earnings rising 28% to $104.1 million, leading to a 27% increase in basic net earnings per share to $0.52. Despite increased investments in research and development, the company managed its cost of sales effectively, leading to a higher gross profit margin.

Key Highlights

1Net sales grew by a significant 20% to $846.9 million in Q1 2003 compared to Q1 2002.
2Net earnings increased by a strong 28% to $104.1 million.
3Basic and diluted EPS saw substantial year-over-year growth of 27% and 28%, respectively.
4International sales experienced robust growth of 27%, outpacing domestic sales growth of 17%.
5Orthopaedic Implants segment sales increased by 24%, while MedSurg Equipment sales rose by 18%.
6Research, development, and engineering expenses increased by 29% to support future product launches.
7The company generated $104.2 million in cash from operations, a significant increase from the prior year.

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2003

Summary

Key Highlights

Frequently Asked Questions